论文部分内容阅读
目的观察格华止与甘精胰岛素联合治疗肥胖型2型糖尿病对空腹血糖、餐后2h血糖、糖化血红蛋白、体重指数的疗效。方法采用动态血糖检测对68例肥胖型2型糖尿病患者给予甘精胰岛素睡前皮下注射,同时三餐前据血糖口服格华止降糖,2~3个月后复查血糖、糖化血红蛋白、体重指数,比较治疗前后血糖、糖化血红蛋白、体重指数的变化,同时观察胰岛素用量的变化。结果格华止降低餐后高血糖明显,同时减轻体重,体重指数下降,抵消胰岛素增重的副作用,增强胰岛素的敏感性,胰岛素用量下降。甘精胰岛素弥补了患者基础胰岛素分泌不足的缺点,同时有效避免夜间低血糖的发生。结论格华止与甘精胰岛素联合治疗肥胖型2型糖尿病,患者空腹血糖、餐后2h血糖、糖化血红蛋白、体重指数均明显下降(P>0.05),胰岛素用量减少,夜间低血糖发生降低。
Objective To observe the effect of combination of Gurvat and insulin glargine in the treatment of obese type 2 diabetes on fasting blood glucose, 2h postprandial blood glucose, glycosylated hemoglobin and body mass index. Methods Eighty-eight patients with type 2 diabetes mellitus were injected subcutaneously with insulin glargine before bedtime at the same time, and their blood glucose levels were measured before meals. The blood glucose, glycosylated hemoglobin, body mass index , Before and after treatment, blood glucose, glycosylated hemoglobin, body mass index changes, while observing changes in insulin dosage. The results of Gehua only reduce postprandial hyperglycemia significantly, while reducing weight, body mass index decline, offset the side effects of insulin gain, enhance insulin sensitivity, decreased insulin dosage. Glargard insulin make up for the shortcomings of patients with basal insulin secretion, while effectively preventing the occurrence of nocturnal hypoglycemia. Conclusion The combination of Gurgut and insulin glargine in the treatment of obese type 2 diabetes patients, fasting blood glucose, postprandial 2h blood glucose, glycosylated hemoglobin, body mass index were significantly decreased (P> 0.05), insulin dosage decreased night hypoglycemia.